Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) - HC Wainwright issued their FY2029 earnings estimates for shares of Leap Therapeutics in a note issued to investors on Wednesday, January 29th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.29) for the year. HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Leap Therapeutics' current full-year earnings is ($1.84) per share.
A number of other research firms also recently issued reports on LPTX. Robert W. Baird downgraded Leap Therapeutics from an "outperform" rating to a "neutral" rating and decreased their price objective for the stock from $9.00 to $1.25 in a report on Wednesday, January 29th. Baird R W cut shares of Leap Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, January 29th.
Get Our Latest Stock Report on LPTX
Leap Therapeutics Stock Performance
NASDAQ LPTX traded down $0.04 on Thursday, reaching $0.52. The company had a trading volume of 806,192 shares, compared to its average volume of 1,371,017. The company's fifty day moving average is $2.74 and its 200-day moving average is $2.73. The firm has a market capitalization of $19.96 million, a price-to-earnings ratio of -0.27 and a beta of 0.15. Leap Therapeutics has a 1-year low of $0.50 and a 1-year high of $4.79.
Institutional Investors Weigh In On Leap Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. Valence8 US LP bought a new position in shares of Leap Therapeutics during the 3rd quarter worth approximately $48,000. HighTower Advisors LLC acquired a new stake in shares of Leap Therapeutics during the third quarter worth $65,000. HB Wealth Management LLC boosted its position in shares of Leap Therapeutics by 103.2% in the fourth quarter. HB Wealth Management LLC now owns 51,500 shares of the company's stock valued at $150,000 after acquiring an additional 26,150 shares during the period. Marshall Wace LLP grew its stake in shares of Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company's stock valued at $156,000 after acquiring an additional 58,094 shares in the last quarter. Finally, Exome Asset Management LLC bought a new position in Leap Therapeutics during the third quarter worth about $264,000. Institutional investors own 30.46% of the company's stock.
About Leap Therapeutics
(
Get Free Report)
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.
Featured Articles
Before you consider Leap Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Leap Therapeutics wasn't on the list.
While Leap Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
